Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2021 Feb 18

PMID 33597926

Citations 7

Authors

Francesca Delle Cese

Andrea Corsello

Marco Cintoni

Pietro Locantore

Alfredo Pontecorvi

Salvatore Maria Corsello

Rosa Maria Paragliola

Affiliations

Soon will be listed here.

Abstract

Objective: The use of once-daily dual-release HC (DR-HC) in primary adrenal insufficiency (PAI) is often associated with benefits in metabolic parameters when compared to immediate-release HC (IR-HC). In this study, we evaluated the effects on clinical, biochemical and metabolic parameters of switching from IR-HC to lower-dose DR-HC given both in once and fractionated daily doses.

Methods: Twenty autoimmune-PAI subjects were included. Patients on 30 mg/day divided in three doses IR-HC regimen (group A) were switched to DR-HC 25 mg/day given in two daily doses (20 mg in the morning and 5 mg at 2.00 p.m.); patients on 25 mg/day divided in two doses IR-HC regimen (group B) were switched to DR-HC 20 mg once daily. Biochemical and metabolic parameters, BMI and quality of life (QoL) were evaluated at the baseline and six months after the switch.

Results: Our small non-randomized study with short follow up showed significant benefits in both group A and group B without any apparent side-effects. After the switch to DR-HC, a significant decrease in adrenocorticotropic hormone (ACTH), HbA1c, total cholesterol, triglycerides, LDL, cholesterol, BMI as well as a significant improvement in QoL, were observed in both groups. At 6 months, ACTH levels were lower in group A while HbA1C and total cholesterol were lower in group B.

Conclusion: The DR-HC is a valid and effective therapeutic strategy to improve the metabolic control and the QoL in PAI. The reduction of ACTH levels with DR-HC regimens reflects a better biochemical control of PAI, obtained by using a lower dose and more physiological HC formulation. Both once-daily and fractionated daily doses of DR-HC showed advantages compared with IR-HC formulation.

Citing Articles

Severe Hyperandrogenism in 46,XX Congenital Adrenal Hyperplasia: Molecular Physiopathology, Late Diagnoses, and Personalized Management.

Cera G, Corsello A, Novizio R, Di Donna V, Locantore P, Paragliola R Int J Mol Sci. 2024; 25(21).

PMID: 39519330 PMC: 11545884. DOI: 10.3390/ijms252111779.

Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy.

Chiloiro S, Vicari A, Mongelli G, Costanza F, Giampietro A, Mattogno P Rev Endocr Metab Disord. 2024; 25(5):855-873.

PMID: 39168952 PMC: 11470908. DOI: 10.1007/s11154-024-09898-6.

Hypoglycaemia in adrenal insufficiency.

Lee S, Baranowski E, Sakremath R, Saraff V, Mohamed Z Front Endocrinol (Lausanne). 2023; 14:1198519.

PMID: 38053731 PMC: 10694272. DOI: 10.3389/fendo.2023.1198519.

Glucocorticoid Replacement for Adrenal Insufficiency and the Development of Non-Alcoholic Fatty Liver Disease.

Meyer G, Gruendl M, Chifu I, Hahner S, Werner J, Weiss J J Clin Med. 2023; 12(19).

PMID: 37835036 PMC: 10573835. DOI: 10.3390/jcm12196392.

Glucocorticoids, their uses, sexual dimorphisms, and diseases: new concepts, mechanisms, and discoveries.

Martinez G, Appleton M, Kipp Z, Loria A, Min B, Hinds Jr T Physiol Rev. 2023; 104(1):473-532.

PMID: 37732829 PMC: 11281820. DOI: 10.1152/physrev.00021.2023.

References

Giordano R, Marzotti S, Balbo M, Romagnoli S, Marinazzo E, Berardelli R . Metabolic and cardiovascular profile in patients with Addison's disease under conventional glucocorticoid replacement. J Endocrinol Invest. 2009; 32(11):917-23. DOI: 10.1007/BF03345773. View

Erichsen M, Lovas K, Fougner K, Svartberg J, R Hauge E, Bollerslev J . Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death. Eur J Endocrinol. 2008; 160(2):233-7. DOI: 10.1530/EJE-08-0550. View

Giordano R, Guaraldi F, Berardelli R, Karamouzis I, DAngelo V, Zichi C . Dual-release Hydrocortisone in Addison's Disease - A Review of the Literature. Eur Endocrinol. 2018; 10(1):75-78. PMC: 5983101. DOI: 10.17925/EE.2014.10.01.75. View

Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E . Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol (1985). 2005; 99(5):2008-19. DOI: 10.1152/japplphysiol.00660.2005. View

Laureti S, Falorni A, Santeusanio F . Improvement of treatment of primary adrenal insufficiency by administration of cortisone acetate in three daily doses. J Endocrinol Invest. 2004; 26(11):1071-5. DOI: 10.1007/BF03345252. View

Johannsson G, Falorni A, Skrtic S, Lennernas H, Quinkler M, Monson J . Adrenal insufficiency: review of clinical outcomes with current glucocorticoid replacement therapy. Clin Endocrinol (Oxf). 2014; 82(1):2-11. DOI: 10.1111/cen.12603. View

Erichsen M, Lovas K, Skinningsrud B, Wolff A, Undlien D, Svartberg J . Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab. 2009; 94(12):4882-90. DOI: 10.1210/jc.2009-1368. View

Johannsson G, Nilsson A, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B . Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab. 2011; 97(2):473-81. DOI: 10.1210/jc.2011-1926. View

Leelarathna L, Breen L, Powrie J, Thomas S, Guzder R, McGowan B . Co-morbidities, management and clinical outcome of auto-immune Addison's disease. Endocrine. 2010; 38(1):113-7. DOI: 10.1007/s12020-010-9359-8. View

10.

Peacey S, Guo C, Robinson A, Price A, Giles M, Eastell R . Glucocorticoid replacement therapy: are patients over treated and does it matter?. Clin Endocrinol (Oxf). 1997; 46(3):255-61. DOI: 10.1046/j.1365-2265.1997.780907.x. View

11.

Debono M, Ross R, Newell-Price J . Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol. 2009; 160(5):719-29. DOI: 10.1530/EJE-08-0874. View

12.

Bornstein S, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer G . Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016; 101(2):364-89. PMC: 4880116. DOI: 10.1210/jc.2015-1710. View

13.

Quinkler M, Nilsen R, Zopf K, Ventz M, Oksnes M . Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol. 2015; 172(5):619-26. DOI: 10.1530/EJE-14-1114. View

14.

Gow R, Koren G, Rieder M, Van Uum S . Hair cortisol content in patients with adrenal insufficiency on hydrocortisone replacement therapy. Clin Endocrinol (Oxf). 2011; 74(6):687-93. DOI: 10.1111/j.1365-2265.2011.04001.x. View

15.

Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker A, Quinkler M . Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab. 2007; 92(10):3912-22. DOI: 10.1210/jc.2007-0685. View

16.

Feek C, Ratcliffe J, Seth J, GRAY C, Toft A, Irvine W . Patterns of plasma cortisol and ACTH concentrations in patients with Addison's disease treated with conventional corticosteroid replacement. Clin Endocrinol (Oxf). 1981; 14(5):451-8. DOI: 10.1111/j.1365-2265.1981.tb00634.x. View

17.

Rousseau E, Joubert M, Trzepla G, Parienti J, Freret T, Vanthygem M . Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency. PLoS One. 2015; 10(8):e0135975. PMC: 4552782. DOI: 10.1371/journal.pone.0135975. View

18.

Oksnes M, Bensing S, Hulting A, Kampe O, Hackemann A, Meyer G . Quality of life in European patients with Addison's disease: validity of the disease-specific questionnaire AddiQoL. J Clin Endocrinol Metab. 2011; 97(2):568-76. DOI: 10.1210/jc.2011-1901. View

19.

Isidori A, Venneri M, Graziadio C, Simeoli C, Fiore D, Hasenmajer V . Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 6(3):173-185. DOI: 10.1016/S2213-8587(17)30398-4. View

20.

Johannsson G, Bergthorsdottir R, Nilsson A, Lennernas H, Hedner T, Skrtic S . Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol. 2009; 161(1):119-30. DOI: 10.1530/EJE-09-0170. View